439 related articles for article (PubMed ID: 18711187)
1. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Raetz EA; Borowitz MJ; Devidas M; Linda SB; Hunger SP; Winick NJ; Camitta BM; Gaynon PS; Carroll WL
J Clin Oncol; 2008 Aug; 26(24):3971-8. PubMed ID: 18711187
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
[TBL] [Abstract][Full Text] [Related]
4. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
5. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Bowman WP; Larsen EL; Devidas M; Linda SB; Blach L; Carroll AJ; Carroll WL; Pullen DJ; Shuster J; Willman CL; Winick N; Camitta BM; Hunger SP; Borowitz MJ
Pediatr Blood Cancer; 2011 Oct; 57(4):569-77. PubMed ID: 21360654
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME
J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Rivera GK; Hudson MM; Liu Q; Benaim E; Ribeiro RC; Crist WM; Pui CH
Blood; 1996 Aug; 88(3):831-7. PubMed ID: 8704238
[TBL] [Abstract][Full Text] [Related]
9. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Sadowitz PD; Smith SD; Shuster J; Wharam MD; Buchanan GR; Rivera GK
Blood; 1993 Feb; 81(3):602-9. PubMed ID: 8427957
[TBL] [Abstract][Full Text] [Related]
10. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
11. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
[TBL] [Abstract][Full Text] [Related]
13. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Winick NJ; Smith SD; Shuster J; Lauer S; Wharam MD; Land V; Buchanan G; Rivera G
J Clin Oncol; 1993 Feb; 11(2):271-8. PubMed ID: 8426204
[TBL] [Abstract][Full Text] [Related]
14. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
15. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Buchanan GR; Rivera GK; Boyett JM; Chauvenet AR; Crist WM; Vietti TJ
Blood; 1988 Oct; 72(4):1286-92. PubMed ID: 3167209
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
17. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
18. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
Horton TM; Whitlock JA; Lu X; O'Brien MM; Borowitz MJ; Devidas M; Raetz EA; Brown PA; Carroll WL; Hunger SP
Br J Haematol; 2019 Jul; 186(2):274-285. PubMed ID: 30957229
[TBL] [Abstract][Full Text] [Related]
20. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Raetz EA; Cairo MS; Borowitz MJ; Lu X; Devidas M; Reid JM; Goldenberg DM; Wegener WA; Zeng H; Whitlock JA; Adamson PC; Hunger SP; Carroll WL
Pediatr Blood Cancer; 2015 Jul; 62(7):1171-5. PubMed ID: 25732247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
